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Tumor cell heterogeneity is a fundamental characteristic of cancer that has
profound implicationsforcancer therapy(1-3). Melanoma, a tumor arising from
pigmented cells, is particularly accessible for the study of tumor heterogeneity.
Metastatic melanoma cells can vary widely in their degree ofpigmentation, cell
morphology, and growth rate (4, 5), and these differences can be observed in
different metastases and even among the various cells within individual lesions
ofpatients with melanoma. There are a number ofbiological factors that could
regulate the phenotypic heterogeneity observed in melanoma cells. One possi-
bility is that melanoma heterogeneity reflects a corresponding diversity in the
phenotype ofnormal cells undergoing melanocyte differentiation. According to
this view, patterns ofgene expression change as cells progress through distinct
cyte lineage. To pursue this idea, we analyzed the anti
phenotype of melanocytes and melanoma (6). Antigens could be grouped into
four categories: (a) not present on melanocytes, (b) expressed by fetal and
newborn melanocytes but notadult, (c) expressed byadult but not fetal/newborn
melanocytes, and (d)equally expressed on fetal, newborn, and adult melanocytes.
anocytes but present on undifferentiated mela-
noma cells were presumed to be markers present on early precursor cells in the
melanocyte pathway. Antigens expressed on fetal and newborn but not adult
melanocytes marked an intermediate phase of melanocyte differentiation. Anti-
gens expressed on adult but not fetal or newborn melanocytes were considered
to be late markers. By comparing antigen expression with other differentiation
luding pigmentation, cell morphology, and tyrosinase activity,
the phenotype of melanoma cell lines was found to correspond to early, inter-
mediate, or late stages of melanocyte differentiation (6). In the present study,
we have investigated the regulation of differentiation markers by melanoma
cells. Clones were established from two melanoma cell lines in order to isolate
individual and distinct phenotypes that represented phenotypes present in the
original tumor. These clones provide stable, relatively homogeneous cell popu-
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lations that have allowed the analysis of the coordinate expression of phenotypic
characteristics by melanoma cells.
Materials and Methods
Cell Culture Studies.
￿
Melanoma cell lines were established as previously described (7).
Parental melanoma cultures and cloned cell lines were maintained in T-25 or T-75 flasks
(Falcon Labware, Oxnard, CA) in Eagle's minimum essential medium supplemented with
7.5% FCS, 2 mM glutamine, I% nonessential amino acids, 100 U/ml penicillin, and 100
jug/ml streptomycin (complete medium). Cultures were maintained at 37°C in 5% C02.
Medium from cultures was changed every 3-4 d and cultures were passaged every 2-3
wk with trypsin (1 mg/ml) and EDTA (0.2 mg/ml) in HBSS. Cultures were tested at
regular intervals for mycoplasma and any contaminated cultures were discarded.
Parental cultures of SK-MEL-131 and SK-MEL-23 were initially cloned by limiting
dilution in 96-well plates (Falcon Labware). All primary clones were subcloned at least
one to two more times before use in experiments. Subclones of SK-MEL-23 were diluted
in complete medium to give a concentration of 3 cells/ml, and then 0.1 ml was added to
each well (at 0.3 cell/0 .1 ml) in a series of 96-well plates. Individual wells were evaluated
under a microscope - 18 h after plating of cells and wells containing only a single cell
were scored and observed for outgrowth of subclones. The nonpigmented clone 22.a was
derived from a BALB/c nu/nu tumor established from the pigmented clone 22 of SK-
MEL-23, and was subcloned as described above. Clone 22.a expressed human HLA but
not mouse H-2 antigens or the mouse leukemia virus antigen glycoprotein (gp)' 70.
Subclones of SK-MEL-131 were established as previously described (8).
For induction studies, cells were cultured in T-25 flasks in complete medium supple-
mented with 12-O-tetradecanoyl-phorbol-13-myristate acetate (PMA) 1 .6 X 10-8 M (PL
Biochem, Division of Pharmacia, Inc., Piscataway, NJ), cholera toxin 10-9 M (Sigma
Chemical Co., St. Louis, MO) or a combination of PMA and cholera toxin.
For determination of doubling times, 2.5 X 105 cells were plated into each well of
Costar 3424 plates (Costar, Cambridge, MA) and trypsinized cells were counted from
duplicate wells with a hemocytometer daily for 6-8 d. Time of doubling was determined
from a least squares regression fit of cell number versus time during logarithmic growth
phase.
Serological Studies.
￿
Table I lists the characteristics and source of antibodies used for
serologic studies (6, 9-14).
The anti-mouse Ig and protein A hemadsorption assays were performed as previously
described (15-17). Antibodies, diluted serially, were incubated with cells cultured in
Falcon 3040 Microtest II plates (Falcon Labware) at room temperature for 1 h. Cells were
then washed three times with PBS and 5% (vol/vol) y-globulin-free FCS in PBS and
incubated for 45 min with a 0.2% (vol/vol) suspension of human erythrocytes conjugated
to anti-mouse Ig or protein A, washed again, and scored for rosetting. Methods for
indirect immunofluorescence assays have been reported previously (18). Cells cultured in
Falcon 3040 Microtest II plates were fixed with a methanol/acetone mixture (1 :1) at 4°C
for 10 min. Plates were incubated with antibodies and then washed as described above.
Cells were incubated with goat anti-mouse Ig conjugated to FITC (Cappel Laboratories,
Cochranville, PA) for 45 min, washed, and examined with epifluorescence.
Tissue Studies.
￿
For evaluation of original tumor tissues, 6-8-Am sections were stained
with hematoxylin and eosin, or Grimelius (silver nitrate) stain for melanin (19).
Pigmentation and Tyrosinase Activity.
￿
Pigmentation was estimated by intensity of brown
or black pigment in cell pellets and confirmed by determining absorbance at 470 nm of
supernatants from 2 X 106 cells solubilized overnight in 0.1 N NaOH/10% dimethylsulf-
oxide. Absorbance by cell pigment was compared to absorbance by a solubilized melanin
'Abbreviations used in this paper:
￿
CALLA, common acute lymphoblastic leukemia antigen; EGFR,
epidermal growth factor receptor; gp, glycoprotein; mCSP, melanoma chondroitin sulfate proteogly-
can.814
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TABLE I
Characteristics and Source ofAntibodies in Serologic Studies
mAb
￿
Antigen detected
￿
Reference
AO10 gp110
￿
6,9
225
￿
gp 170; epidermal growth factor receptor (EGFR)
￿
10,23
L243
￿
gp 33, 27; la antigens (HLA-DR)
￿
11,27
B5.2
￿
gp 240, >400; melanoma chondroitin sulfate proteoglycan (mCSP)
￿
6,12
Mill
￿
gp 110
￿
6,12
NL-1
￿
gp 100; common acute lymphoblastic leukemia antigen (CALLA)
￿
6, 13
C350
￿
gp 180
CF21
￿
Antigen of mature melanosomes
TA99
￿
gp 75; antigen of mature melanosomes
￿
14
Me] 1
￿
Heat labile
￿
6, 15
M144
￿
Heat labile
￿
6, 12
standard (Sigma Chemical Co.). Tyrosinase activity was determined by the method of
Pomerantz (20), modified as previously described (21). Measurements of tyrosinase were
performed in triplicate from cells extracted in PBS, 0 .5% Nonidet-P40 (NP-40), 50 AM
tyrosine, 50 PM DOPA and 5 ACi/ml 3',5'-['H]tyrosine (New England Nuclear, Boston,
MA). Tyrosinase activity was expressed as the ratio of 'H20 formed by (106 test cells)/(106
tyrosinase-negative renal cancer cell line SK-RC-6). Ratios of gH20 calculated per milli-
gram of protein of cell extracts gave results within 20% of ratios calculated from cell
number.
Radioimmunoprecipitation. Analysis of immunoprecipitates was performed as previ-
ously described (22). Cultured cells were labeled with [sH]glucosamine (New England
Nuclear) for 72 h. 0.5% NP-40 cell lysates were prepared and equivalent sH counts per
minute (determined by precipitation at 4°C with 10% vol/vol TCA) of lysate were used
for immunoprecipitation with each antibody. Immunoprecipitation was carried out with
monoclonal antibody plus rabbit anti-mouse Ig and PA-Sepharose (Pharmacia Inc.) and
was analyzed on 9% SDS-PAGE.
Results
Serological Typing ofMelanomas: Characterization ofAntigenic Phenotypes
and Selection ofCell Linesfor Subcloning
28 melanoma cell lines from 26 patients were evaluated for antigen expression,
tyrosinase activity, cell morphology, and pigmentation (Fig. 1). 11 antigen systems
were analyzed in the present study because they define subsets of melanomas,
have distinct patterns of expression on fetal, newborn, and adult melanocytes,
and have been interpreted to map to different stages of melanocyte differentia-
tion (early, intermediate, or late). Antigens A010, epidermal growth factor
receptor (EGFR), melanoma chondroitin sulfate proteoglycan (mCSP), and la
are early markers of melanocyte differentiation, antigens M111 and common
acute lymphoblastic leukemia (antigen) (CALLA) are markers of an intermediate
stage, and antigens C350, CF21, TA99, Mel 1, and M144 are late markers
(Table 1) (6, 23).
Two melanoma cell lines (highlighted in Fig. 1) were selected for more detailed
studies: (a) SK-MEL-131, derived from patient FD, has an epithelioid morphol-HOUGHTON ET AL.
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FIGURE 1 .
￿
Serologic typing of melanoma cell lines for melanocyte differentiation markers.
Antigenexpression is graded by titers: +, 1/200 to 1/1,000; ++,>1/1,000 to 1/10,000; +++,
>I/10,000 to 1/100,000; ++++, >1/100,000. Morphology (MORPH.): E, epithelioid; S,
spindle; D, dendritic. Pigmentation is determined as outlined in Materials and Methods.
Tyrosinase activity is expressed as the ratio of melanoma/control renal cancer culture (SK-
RC-6).
ogy, lacks pigmentation, and expresses early melanocyte markers, and (b) SK-
MEL-23 from patient AP contains a mixture of spindle and polydendritic cells,
is deeply pigmented, expresses high tyrosinase activity and late markers, and is
representative ofcells at a late stage of melanocyte differentiation.
Heterogeneity in Tumors from Patients FD and AP
There is a high degree of variability in cell morphology, pigmentation, and
expression ofmelanocyte differentiation antigens in tissue sections of metastatic
melanoma lesions (4, 12, 14, 24). Characteristically, individual differentiation
antigens are detected on only a proportion ofcells within tumor specimens. For
example, we have found that la, mCSP, M111, CF21, TA99, and C350 antigens
are expressed on distinct subsets of melanoma cells in reactive tumors (12, 14).
To investigate this phenotypic heterogeneity of melanoma, we examined the
phenotype ofcells in the original tumor lesions of patients FD and AP. The cell
line SK-MEL-131 was established from an axillary lesion resected from patient
FD and the cell line SK-MEL-23 was derived froma surgically resected metastatic
tumor in the axilla ofpatient AP. Tissue sections fromparaffin-embeddedblocks
ofthese lesions were examined for cell morphology, pigmentation, and antigen
expression . Substantial variability in cell shape and pigmentation was observed.
Each lesion contained a mixture of epithelioid and spindle cells (Fig. 2A) and
MELANOMA A010 EGFr la MCSP
ANTIGEN SYSTEM
M111 CALLA C350 CF21 TA99 Mel1 M144 MORPH. PIGMENT
TYR,
ASE
SK-MEL-31 E 1 .0
SK-MEL-186 E 1 .0
SK-MEL-187 E 1 .0
SK-MEL-178 + ++++ ++++ ++++ E 1 .0
SK-MEL-37 E 1 .0
DX-3 E 1 .0
SK-ME1481 ++ ++++ ++++ +++ E 1 .0
SK-MEL-170 - ++++ ++++ ++ E-S 1 .0
SK-MEL-173 E-S 1 .9
SK-MEL-176 S 1 .4
SK-MEL-81 - + - ++++ E-S 1 .1
OX-5 E-S 1 .2
SK-MEL-118 ++ +++ ++ E-S 1 .0
SK-MEL-13 - - +++ ++ S +or- 1 .9
SK-MEL-30 S 5 .5
SK-MEL-29 + - - +++ + S +or- 1 .6
OX-2 S +or- 1 .8
SK-MEL-28 + +++ s +or- 1 .4
SK-MEL-75 S +or- 1 .6
McWo s +or- 1 .7
SK-MEL-127 ++ +++ +++ ++ ++ S-D 4 .1
SK-MEL-130 ++++ +++ +++ + + S 2.2
SK-MEL-64 ++++ +++ ++++ + - S 3.0
SK-MIL-23 S-D 13 .3
SK-MEL-19 ++++ +++ ++++ +++ + S-D 7 .8
SK-MEL-110 +++ +++ +++ +++ - S-D +or- 2.5
SK-MEL-21 ++++ ++ +++ +++ + S 8.4
SK-MEL-188 ++++ ++++ ++++ ++ + S 7 .6816
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FIGURE 2 .
￿
Histology of representative areas of melanoma from patients FD and AP (A)
Tissue section from an axillary lesion of patient FD demonstrating a mixture of epithelioid
(top-left) and spindle (bottom-right) tumor cells (stained with hematoxylin and eosin, x 200). (B)
Tissue section from an axillary lesion of patient AP demonstrating a mixture of pigmented
and nonpigmented tumor cells (Grimelius strain, x 200). SK-MEL-131 was derived from the
lesion in A and SK-MEL-23 from the lesion in B.HOUGHTON ET AL.
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areas of pigmented and nonpigmented tumor (Fig. 2B). We were unable to
measure antigen expression, inasmuch as none of the determinants ofdifferen-
tiationantigens that we tested were stable afterparaffinization-deparaffinization.
Phenotypes ofClonesfrom Melanoma Cell Lines SK-MEL-131 and SK-MEL-
23: Antigen Expression, Pigmentation, and Tyrosinase Activity
We investigated whetherthe various phenotypes observed in tumors ofpatients
FD and AP were expressed in cloned cell lines derived from these lesions. Clones
were established from early passage cells frozen shortly after the original tumor
cells were established in culture. The cell line SK-MEL-131 from patient FD was
cloned at passage 7 and SK-MEL-23 from patient AP was cloned at passage 8.
Each clone was subcloned two to three times and then evaluated for expression
ofantigens and other differentiation-related characteristics.
17 clones were studied from SK-MEL-131 and 19 clones from SK-MEL-23.
Clones from each parental cell line varied in cell morphology and pigmentation
(Figs. 3 and 4). Differentiation traits were expressed in a coordinate fashion on
cloned cell lines. Expression of early antigens correlated with an epithelioid or
spindle shape, an absence ofpigment, and low or nodetectable tyrosinase activity .
Expression of late markers corresponded to a spindle or dendritic morphology
and presence ofpigment and tyrosinase activity. Fig. 5 lists the characteristics of
representative clones derived from SK-MEL-131 and SK-MEL-23. Clones from
SK-MEL-131 ranged from early to intermediate stage ofmelanocyte differentia-
tion, and clones from SK-MEL-23 ranged from intermediate to late stage.
Epithelioid clones from SK-MEL-131 (e.g., clone 1 .36-1-5) expressed only early
melanocyte markers and no detectable tyrosinase activity, while spindle shaped
clones (e.g., clone 3.44) expressed intermediate markers, tyrosinase activity, and
light pigmentation. 18 of 19 clones of SK-MEL-23 were pigmented, had mod-
erate to high levels oftyrosinaseactivity, and expressed late melanocyte markers.
The 19th subclone of SK-MEL-23, clone 22.a, was nonpigmented and had no
detectable tyrosinase activity. Clone 22.a was derived after passage of the pig-
mented parental clone 22 through nu/nu mouse (see Materials and Methods).
Clone 22 expressed the late marker C350 and the melanosomal antigens TA99,
and CF21, but not the early markers la, mCSP, and M111. In contrast, clone
22.a did not express late markers (C350-, TA99-, and CF21-) but did express
la, mCSP, and M111 .
To evaluate whether growth rate might be related to expression of differen-
tiation traits, doubling times during logarithmic growth phase were measured in
selected clones. The early stage clone 1.36-1-5 had a doubling time of 54 h and
intermediate stage clones (clones 3.44, 22.a, and 6113) doubled every 48-54 h.
Doubling times of late stage clones were 52 h (clone 22), 79 h (clone 19), and
>120 h (clone 711). These results show that some melanoma clones correspond-
ing to late stages of differentiation grow at a very slow rate, but the rate of
growth of clones at other stages was similar. All subclones ofSK-MEL-131 and
SK-MEL-23 have been maintained for more than 2 yr in culture and phenotypes
have remained stable over this period unless tissue culture conditions were
manipulated (e.g., deprivation ofserum, very high cell densities).818
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MGnno 3
￿
Parental cell line 9K-MmEc'B! uuufour ouhdones : (A) clone 1 .36-1-5 contains
epithelioid, nonpigmented cells ; (B) clone 1-9 contains epithelioid, nonpigmented cells; (C)
clone 2.45 contains epithelioid and spindle, nonpigmented cells ; and (D) clone 3.44 contains
spindle, lightly pigmented cells . A description of phenotypic traits of these clones is given in
Fig. 5. X 360 .
Further
￿
Differentiation
￿
ofMelanoma Program
￿
Cells:
Induction ofDifferentiation
To establish that differentiation characteristics on melanoma cells can be
regulated in a coordinate fashion, four clones were evaluated in induction studies .
Clones were selected that corresponded to early (clone 1 .36-1-5), intermediate
(clones 8,44 and clones 22.a), and late (clone 22) stages of differentiation . Each
clone was cultured in the presence of the p6orbol ester PMA, cholera toxin, or
a combination ofPMA and cholera toxin .
Each clone responded ;uadistinct manner tninducing agents . Clone 3.44 was
induced to differentiate by PMA and clones 22.a and 22 by cholera toxin,
whereas clone 1 .36-1-5 was induced to undergo onlyminor changes in phenotype
by eitherPMA or cholera toxin . Thus, each clone could be induced to undergo
o shift in differentiation characteristics (Fig . 6)` but the degree of alterationHOUGHTON ET AL.
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Parental cell line SK-MEL-23 and six subclones: (A) clone 6113, (B) clone 6115,
22-1, (D) clone 15, (E) clone 19, (F)clone711. Clones 6113 (A)and6115 (B)eon
cells with light to moderate pigmentation . Clone 22-1 (C) contains deep
. Clones 15 (D), 19 (E), and 711 (E) contain dendritic
with deep pigmentation . A description ofphenotypi
5 . x 360 .
varied-only minimal changes were detected after induc
1.36-1-5 by the combination ofPMA and cholera toxin, but a major s
differentiation state of clone 22.a from intermedi
observed during exposure to cholera toxin. Major alterations in
not clearly evident until after 2-3 wk . For example, during
22.a, there was a gradual increase of pigment, appearance of C350 an
between days 4 and 7, and appearance of antigens CF21 andTA99 between the820
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FIGURE 5.
￿
Phenotypic characteristics of subclones of SK-MEL-131 and SK-MEL-23. See
legend to Fig. 1 (antigen expression, morphology, pigmentation, and tyrosine activity).
second and third week (CF21 was expressed before TA99). Specifically, the
following observations were made:
Parental cell lines SK-MEL-131 and SK-MEL-23. No changes in antigen
expression were observed in SK-MEL-131 during incubation with PMA or
cholera toxin, although PMA did induce an increase in theproduction ofspindle-
shaped cells. No changes were detected in the antigenic profile of SK-MEL-23
in the presence of either cholera toxin or PMA. Cholera toxin induced a
polydendritic morphology and increased pigmentation in SK-MEL-23 cells, and
this effect was inhibited by PMA.
Clone 1.36-1-5 (early stage). The combination of PMA and cholera toxin
induced a decrease in the expression of early markers AO10, mCSP, and Ia, and
a concurrent induction ofthe intermediate marker CALLA and the later marker
C350 (Fig. 6). These changes in antigen expression were accompanied by the
occasional appearance of dendritic cells, but the cells remained nonpigmented
and tyrosinase-negative (Fig. 7A). Once clone 1.36-1-5 was induced with PMA
and cholera toxin, the induced antigenic changes were maintained when PMA
and cholera toxin were removed from the culture medium. No phenotypic
changes were observed when clone 1 .36-1-5 was exposed to either PMA or
cholera toxin alone.
Clone 3.44 (intermediate stage).
￿
PMA induced long dendritic processes on the
spindle-shaped clone 3.44 and augmented tyrosinase activity and melanin syn-
thesis (Fig. 7B). These changes wereaccompanied by a change inantigen profile,
with downregulation ofthe early markers mCSP and la and induction ofthe late
markers C350 and CF21 (Fig. 6). After induction with PMA, the altered
phenotype was maintained in the absence of PMA. Similar but less pronounced
changes were observed in the presence of PMA and cholera toxin, and cholera
toxin alone had no effect on the phenotype of clone 3.44.
Clone 22.a (intermediate stage).
￿
The most profound change in differentiation
program was observed in clone 22.a during induction with cholera toxin. During
induction, clone 22.a, which was nonpigmented and tyrosinase-negative, became
pigmented and tyrosinase-positive (Figs. 7C and 8). Early and intermediate
MELANOMA
CLONES A010 EGFr la MCSP
ANTIGEN SYSTEM
M111 CALLA C350 CF21 TA99 Mel 1 M144 MORPH . PIGMENT
TYR'
ASE
SK-MEL-131
1-9 E 10
1 .36-1-5 E 10
1-13 E 12
2 .45 - - +++ ++ E -S 14
345 S 15
3 .44 S 18
SK-MEL-23
22 a S 09
6113 ++++ +++ +++ ++ ++ S 99
8114 S 69
22 ++++ +++ ++++ +++ - S 12 .4
1111 ++++ +++ + +++ + D 21 2
19 S-D 34 .1CSP
la
HOUGHTON ET AL .
￿
82 1
SK-MEL-131 SK-MEL-131 SK-MEL-23
C1 .1 .36-1-5
￿
C1 . 3.44
￿
Cl . 22.a
100
50
0
,00
50
ANTIBODY DILUTION
FIGURE 6 .
￿
Serologic typing of subclones 1.36-1-5 (derived from SK-MEL-131 parental cell
line), 3 .44 (SK-MEL-131), and 22.a (SK-MEL-23) for expression of antigens A010, mCSP
(CSP), la, CALLA, M111,C350, CF21,and TA99 in induced (solid circles) and control (open
circles) cultures. Clone (Cl.) 1 .36-1-5 was induced with cholera toxin and PMA, clone 3.44
with PMA, and clone 22 .a with cholera toxin as described in the text. Expression of antigens
AO 10, CSP, la, CALLA, M111, and C350 were tested by anti-mouse Ig assays : antibody
dilutions were 1/1,000, 1/10,000, 1/100,000, and 1/1,000,000 . Expression of CF21 and
TA99 were tested by indirect immunofluorescence assays: antibody dilutions were 1/100,
1/1,000, 1/10,000, and 1/100,000 .
100
cn CALLA 50
J
J
W
U
w 100
y M111 50
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Induction of subdones 22, and 22 of SK-MEL-23. (A) control culture of clone
altars of clone 22.a induced with cholera toxin, (C) control culture ofclone 22, (D)
clone 22 induced with cholera toxin. X 3
d cultures: (A) clone 1 .36-1-5
Oy clone 3.44 shows an
.a becomes pigmented whenHOUGHTON ET AL .
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FIGURE 9.
￿
Immunoprecipitation of antigens from control (C) or induced (I) cultures of
subclone 22.a of SK-MEL-23 . Cultures were induced with cholera toxin (10-9 M) . Cells were
metabolically labeled with ['Hlglucosamine . CSP, gp240/>400 ; la, gp33/27 ; M1II, gp110 ;
TA99, gp75 .
markers (mCSP, la, and M111) were downregulated while late markers (C350,
CF21, and TA99) were induced (Fig . 6) . These serologic results were confirmed
by radioimmunoprecipitation of antigens from induced and control cells (Fig .
9) . The change in differentiation program produced by cholera toxin was stable
and was not reversed by removing cholera toxin from the culture medium . PMA
alone and the combination ofPMA and cholera toxin induced clone 22.a cells
to become more dendritic, but there was no change in other traits .
Clone 22 (late stage). Cholera toxin induced clone 22 to become heavily
pigmented and polydendritic (Fig . 8) . A decrease in the expression of the
melanosomal antigen TA99 was observed, but no other antigen changed expres-
sion (data notshown) . The doubling time of clone 22 increased from 52 to >120
h after 21 d of exposure to cholera toxin . PMA alone and the combination of
PMA and cholera toxin produced elongated, spindle-shaped cells but no other
alteration, again suggesting that exposure to PMA blocked the differentiating
effects of cholera toxin .
Discussion
Cells of the melanocyte lineage undergo phenotypic changes as they migrate
from the neural crest to their final destination in the skin (25, 26). The most
striking trait ofmature melanocytic cells is the presence of the pigment melanin .
The synthesis of melanin is regulated by the specialized cellular enzyme tyrosin-
ase, and the expression of melanin and tyrosinase activity is associated with the824
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expression ofa set ofcell surfaceand melanosomal antigens (6, 23, 27). In earlier
studies, we have proposed a model for melanocyte differentiation based on the
expression ofthese traits by a panel ofmelanoma cell lines and by cultured fetal,
newborn, and adult melanocytes (6). The present investigations with cloned
melanoma cell lines have extended these studies and have confirmed that the
pattern of antigen expression is related to other differentiation traits, such as
pigmentation, tyrosinaseactivity, and morphology. Theinduction ofcoordinated
changesin the differentiation program of these clones by PMAandcholera toxin
was in accordance with predictions from this model.
There are two major stages of melanocyte differentiation in this model-early
and late-with an intermediate stage that characterizes the transition from early
to late. Melanoma cellsatan early stage appear to becommitted tothemelanocyte
phenotype, because they express markers that characterize the melanocyte lin-
eage (6) and they stably maintain this phenotype unless induced to differentiate.
The late stage coincides with the emergence of a specialized phenotype, charac-
terized by the appearance of pigment and associated markers. The transition
from the early to the mature phenotype is associated with a coordinated change
in the pattern of expression of differentiation traits. Even within a stage of
differentiation, there appears to be a hierarchy for expression of traits. For
instance, as melanocytic cells mature, late antigens do not appear synchronously
but rather are expressed in a specific order-C350, then CF21, followed by
TA99.
Each of these differentiation traits can be expressed by melanomas in a
heterogeneousfashion. For example, it is not unusual to observe a nonpigmented
metastasis next to a pigmented metastasis in a patient with melanoma. Likewise,
melanocyte differentiation antigens are characteristically expressed by only a
subset of melanoma cells within individual lesions (12, 24). These observations
have led us to consider whether the remarkable phenotypic heterogeneity ob-
served in melanomas is due to the coexistence of populations ofcells at different
stages of differentiation. It is clear from our experiments that melanomas are
not frozen at a specific stage of differentiation. Appropriate signals, such as
phorbol esters, activators ofcellular cyclic AMP (e.g., cholera toxin, melanocyte-
stimulating hormone) or cyclic AMP analogues can induce melanoma cells to
undergo variable degrees of differentiation (27-34). In particular, cyclic AMP
has been implicated in the regulation of melanin synthesis in vivo and our
experiments suggest that cyclic AMP and other pathways may be involved in the
coordinated upregulation and downregulation ofa family oftraits in melanocytic
cells. When melanoma clone 22.a was induced to mature, late markers (melanin
synthesis, tyrosinase activity, the melanosomal markers TA99 [gp75] and CF21,
and the C350 cell surface glycoprotein [gpl80]) were expressed, while in the
same cells early and intermediate markers (Ia antigens, MI I I [gpI 10], CALLA
[gpI00], and the melanoma chondroitin sulfate proteogiycan antigens [mCSP])
were simultaneously downregulated. We have noted that melanoma clones vary
in their response to cholera toxin or PMA. The response or lack of response by
individual clones to induction must be related to biological traits that differ from
one clone to another. One explanation is that intracellular pathways mediatingHOUGHTON ET AL.
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the differentiation program change as cells proceed through the melanocyte
lineage. Alternatively, heterogeneity in expression of receptors or response to
these signals is unrelated to the differentiation program.
The regulation of la (class II major histocompatibility) antigens by melanoma
cells is ofparticular interest. la antigensare not expressed by mature melanocytes
(unless induced by gamma interferon [35]), but they are constitutively expressed
by a proportion of melanomas (6, 35-37) . One explanation for this constitutive
expression is that la expression is regulated by events occurring during the
process ofmalignant transformation. In support ofthis hypothesis, recent exper-
iments have demonstrated the induction of la by the introduction of ras onco-
genes into melanocytes (38). In contrast, serological typing of melanomas has
shown that expression of la on individual tumors corresponds to stage of
melanocyte differentiation (6). Our interpretation ofthisdatais that la expression
is regulated during melanocyte differentiation, the assumption being that la is
expressed by precursor cells in the melanocyte lineage. Induction experiments
with cloned melanoma cells confirm that la can be regulated during differentia-
tion ofmelanoma cells. For instance, clone 22.a ofSK-MEL-23 (Ia') downregu-
lated the expression of la during transition from an intermediate to a late
differentiation program. The two scenarios, transformation and differentiation,
are not mutually exclusive. The results of our experiments suggest that both
transformation-related events and the differentiation program can regulate la
expression on melanocytic cells.
The parental melanoma cell lines SK-MEL-131 and SK-MEL-23 each con-
tained a mixture of cell populations that reflected a corresponding diversity
present in the original tumor lesions. These different cell populations were
apparent in early passage cultures, and could be maintained in parental cell lines
even after long-term in vitro culture (unpublished observations). In contrast to
the results of the study by Cillo et al. (39), we found that the phenotypes of
cloned subpopulations were stable if culture conditions were not manipulated.
These observations suggest that, at equilibrium conditions, parental cultures
maintain a mixture of phenotypes that correspond to various stages ofdifferen-
tiation. Several factors may have impact on the diversity of populations present
within the parentalstrains: (a)small subpopulations in stochastic equilibrium may
be competent for only a particular signal or set ofsignals, and conversely a given
signal for differentiation may, affect only a small population of cells; (b) the
degree ofvariation in the differentiation stage of melanoma cells within a lesion
or cell line appears to be limited; thus, in studies with cell lines we have not
observed mature melanoma cells mixed with early stage cells, but rather have
seen cells at an early stage coexist with intermediate stage, and intermediate cells
with late stage cells; and (c) within the context of the parental population,
induction ofdifferentiation in a subpopulation may produce a decreased growth
advantage, selecting against differentiation of the parental culture.
s The inability of Cillo et al. to detect a differentiation pattern ofantigen expression on melanoma
cells is probably due to the limited panel of monoclonal antibodies and cell strains studied. Most of
the monoclonal antibodies in this study (e.g., anti-HLA-A,B,C) did not distinguish identifiable subsets
(although analysis of their data does suggest that expression of CALLA is inversely related to la
antigens).826
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The fact that tumors can be composed ofcomplex populations of cells should
be taken into consideration in theevaluation ofagents that induce differentiation.
Such agents can be used to induce terminal differentiation of tumor cells (40) or
to manipulate the expression ofantigens on tumor cells, for instance, to optimize
antigen expression on lesions in preparation for targeting with monoclonal
antibodies. An agent that induces differentiation of cells at one stage may not
have the same biological effect on cells at another stage. In addition, agents may
interfere with each other in effective induction of differentiation. For instance,
we and others have observed that PMA can block the induction of late differ-
entiation markers in melanoma cells (41). Cloned cell lines have definite advan-
tages over parental cell strains in the analysis ofagents that induce shifts in the
differentiation state. In this regard, neither PMA nor cholera toxin alone or in
combination was able to induce major changes of phenotype in 10 noncloned,
established melanoma cell lines (Houghton, A. N., and F. X. Real, unpublished
observation) including SK-MEL-131 and SK-MEL-23. Cloned subpopulations
permitted a dissection of the regulation of differentiation traits in distinct
subpopulations. Understanding signals involved at each stage of melanocyte
differentiation will lead to strategies aimed at the terminal differentiation of
melanoma cells in vivo.
Summary
Phenotypic heterogeneity is a characteristic feature oftumor lesions in patients
with melanoma. Variability can be observed in cell morphology, pigmentation,
and antigen expression. To test whether phenotypic heterogeneity could be the
result ofevents regulated during cell differentiation, we evaluated the expression
of a panel of differentiation traits on melanoma cells. Metastatic melanoma
lesions from two patients, designated FD and AP, were examined histologically
and found to contain mixed populations ofcells. Established melanoma cell lines
derived from each of these lesions were subcloned at early passage in culture
(passages 7 and 8) to create a panel of clones derived from each tumor. There
was heterogeneity in the expression of differentiation-related traits in clones,
corresponding to distinct phenotypes observed within the original tumors. Clones
from patient FD corresponded to early to intermediate stages of melanocyte
differentiation, and clones from patient AP ranged from intermediate to late
stages. The influence of cholera toxin and PMA. on differentiation of parental
cultures and subclones was studied. Results of induction studies demonstrated a
number offeatures of differentiation ofmelanoma cells: (a) regulation ofdiffer-
entiation traits is coordinated as a program of traits expressed sequentially at
specific stages; (b) early traits, such as the epidermal growth factor receptor and
the melanoma chondroitin sulfate proteoglycan antigen, are downregulated as
melanoma cells differentiate, whereas late markers, includingmelanin, tyrosinase
activity, and antigens expressed in mature melanosomes, are upregulated; (c) la
(class II major histocompatibility) antigens are characteristically expressed on
melanomas corresponding to early or intermediate stages of differentiation and
are regulatedaspart ofthedifferentiation program; (d) minimal changes in stage
ofdifferentiation were observed during induction ofparental cultures with eithercholera toxin or PMA, whereas definite shifts in differentiation could be induced
in selected cloned subpopulations. We conclude that melanoma cells are not
frozen at a specific stage of differentiation, but rather are capable of differen-
tiating when exposed to appropriate signals. Diversity in the differentiation state
of melanoma cells can account for much of the phenotypic heterogeneity ob-
served in melanoma lesions.
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